Shenzhen Edge Medical Co (HKSE:02675) Total Equity: HK$1,324.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02675 Shenzhen Edge Medical Co Ltd HKSE:02675
11 GF Score
Price HK$38.30
! 3 Warning Signs
View Full Analysis

What is Shenzhen Edge Medical Co Total Equity?

Shenzhen Edge Medical Co HKSE:02675 -3.14% 11 Total Equity is HK$1,324.2 Mil as of Dec. 2025. GuruFocus rates HKSE:02675 with a GF Score™ of 11/100. The stock has 3 warning signs investors should review.

Shenzhen Edge Medical Co's total equity for the quarter that ended in Dec. 2025 was HK$1,324.2 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shenzhen Edge Medical Co Total Equity Historical Data

* Premium members only.

The historical data trend for Shenzhen Edge Medical Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shenzhen Edge Medical Co Total Equity Chart

Shenzhen Edge Medical Co Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
1,573.23 1,345.22 1,324.25

Shenzhen Edge Medical Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity 1,573.23 0.00 1,345.22 1,294.82 1,324.25
HKSE:02675
11GF Score
Shenzhen Edge Medical Co Ltd HKSE:02675
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shenzhen Edge Medical Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shenzhen Edge Medical Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1530.862-206.617
=1,324.2

Shenzhen Edge Medical Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1530.862-206.617
=1,324.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,324.2 Mil mean?
Shenzhen Edge Medical Co (HKSE:02675) has a Total Equity of HK$1,324.2 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Shenzhen Edge Medical Co and its competitors.
Is Shenzhen Edge Medical Co's Total Equity too high?
Shenzhen Edge Medical Co's current Total Equity is HK$1,324.2 Mil. Overall, Shenzhen Edge Medical Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Shenzhen Edge Medical Co's Total Equity compare to ABT and SYK?
Shenzhen Edge Medical Co's Total Equity of HK$1,324.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shenzhen Edge Medical Co and its competitors. Shenzhen Edge Medical Co's current Total Equity is HK$1,324.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shenzhen Edge Medical Co stock overvalued right now?
Shenzhen Edge Medical Co (HKSE:02675) has a current Total Equity of HK$1,324.2 Mil. The current Total Equity is HK$1,324.2 Mil. Shenzhen Edge Medical Co's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shenzhen Edge Medical Co (HKSE:02675), the current Total Equity is HK$1,324.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shenzhen Edge Medical Co Business Description

Other Exchanges R5Z:Germany
Address Baolong Street, Room 1901, Building 2B, Smart Park Phase II, Longgang District, Shenzhen, CHN
Shenzhen Edge Medical Co Ltd is principally engaged in the designing, research and development, manufacturing and sale of surgical robots. It has a pipeline of three products and product candidates covering various models at different development stages to capture the market potential in surgical robots, including Edge Multi-Port Endoscopic Surgical Robot and Edge Single-Port Endoscopic Surgical Robot for MIS, as well as Edge Bronchoscope Robot for non-invasive surgery. The company derives revenue principally from the sales of surgical robot systems, instruments and accessories, and provision of services. Geographically, the maximum revenue is generated from the Chinese mainland, followed by Asia (other than Chinese Mainland), Europe, and Others.
11GF Score

Get the complete analysis for HKSE:02675

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$38.30
Price